LRRC23: A Potential Drug Target or Biomarker for Various Diseases

Target Name: LRRC23

NCBI ID: G10233

LRRC23

LRRC23: A Potential Drug Target or Biomarker for Various Diseases

LRRC23, also known as leucine-rich protein B7, is a protein that is expressed in various tissues throughout the body. It is a member of the B7 family of cytoplasmic proteins, which are involved in various cellular processes such as inflammation, antigen presentation, and cell adhesion. One of the unique features of LRRC23 is its ability to interact with the protein PD-L1, which is a known regulator of immune responses. This interaction between LRRC23 and PD-L1 has led to the hypothesis that LRRC23 may be a drug target or biomarker for various diseases.

The protein LRRC23 is composed of 23 amino acid residues and has a calculated molecular weight of 21.1 kDa. It is expressed in various tissues, including the liver, spleen, kidney, heart, and pancreas. LRRC23 is involved in various cellular processes, including the regulation of inflammation, cell adhesion, and antigen presentation.

One of the unique features of LRRC23 is its ability to interact with the protein PD-L1. PD-L1 is a known regulator of immune responses and has been implicated in various diseases, including cancer, autoimmune diseases, and neurodegenerative diseases. LRRC23 has been shown to interact with PD-L1 and to regulate its activity. This interaction between LRRC23 and PD-L1 has led to the hypothesis that LRRC23 may be a drug target or biomarker for various diseases.

LRRC23 has been shown to play a role in the regulation of inflammation. LRRC23 is involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha, IL-12, and IL-18. It is also involved in the regulation of the production of anti-inflammatory cytokines, such as IL-10 and IL-12. These cytokines are involved in the regulation of various cellular processes, including inflammation, immune responses, and cell adhesion.

LRRC23 is also involved in the regulation of cell adhesion. LRRC23 is a member of the cadherin family of proteins, which are involved in cell-cell adhesion. It is expressed in various tissues and has been shown to be involved in the regulation of cell adhesion, including the regulation of cell-cell adhesion in various tissues, such as the regulation of tight junction formation in the epithelial tissue and the regulation of adherens junction formation in the muscle tissue.

LRRC23 is also involved in the regulation of antigen presentation. LRRC23 is a member of the major histocompatibility complex (MHC) class I, which is involved in the presentation of antigens from exogenous sources to the immune system. It is expressed in various tissues and has been shown to play a role in the regulation of antigen presentation, including the regulation of the loading of antigens into the endoplasmic reticulum (ER) and the regulation of the translation of antigens into the cell surface.

In conclusion, LRRC23 is a protein that is involved in various cellular processes, including the regulation of inflammation, cell adhesion, and antigen presentation. Its interaction with the protein PD-L1 has led to the hypothesis that LRRC23 may be a drug target or biomarker for various diseases. Further research is needed to confirm this hypothesis and to fully understand the role of LRRC23 in the regulation of various cellular processes.

Protein Name: Leucine Rich Repeat Containing 23

The "LRRC23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets